Literature DB >> 24136021

Influenza A/H1N1 in pediatric oncology patients.

Amit Dotan1, Shalom Ben-Shimol, Yariv Fruchtman, Yonat Avni-Shemer, Joseph Kapelushnik, Miri Ben-Harush, Noga Givon-Lavi, Eugene Leibovitz, David Greenberg.   

Abstract

BACKGROUND: Our aim was to determine the clinical and epidemiological features of pandemic influenza A/H1N1 in immunocompromised children with solid tumors and hematological malignancies. PATIENTS AND METHODS: A prospective study was conducted during the H1N1 pandemic between August 2009 and February 2010 in a pediatric hematology-oncology unit. Demographic and clinical data were obtained from all children with suspected H1N1 infection (high fever with or without respiratory symptoms). Laboratory diagnosis of influenza A/H1N1 was performed by means of polymerase chain reaction analysis of nasopharyngeal wash specimens.
RESULTS: We identified 57 episodes of suspected influenza A/H1N1 infection in 40 children. In all episodes, children were treated with oseltamivir and antibiotics until influenza A/H1N1 results were received. Of all episodes, 13 (22.8%) tested positive for influenza A/H1N1. Two of the H1N1-positive children (15.4%) had been previously immunized against influenza A/H1N1. No differences between H1N1-positive and H1N1-negative children were noted in terms of demographic features, clinical presentation, laboratory findings, and underlying disease.Three polymerase chain reaction-positive (23.0%) children and 1 H1N1-negative (2.3%) child were admitted to the pediatric intensive care unit and were mechanically ventilated (P=0.03). One (7.7%) H1N1-positive patient died versus none of the H1N1-negative patients (P=0.2). The condition of all other children in both the groups improved rapidly during hospitalization.
CONCLUSIONS: Febrile hospitalized pediatric oncology patients, with and without pandemic influenza A/H1N1, had a similar demographic and clinical presentation with a relatively good outcome. This was probably because of early antiviral treatment and possibly because of the relatively low virulence of the virus. Immunization should be encouraged in these patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24136021     DOI: 10.1097/MPH.0000000000000043

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  4 in total

1.  Frequent Respiratory Viral Infections in Children with Febrile Neutropenia - A Prospective Follow-Up Study.

Authors:  Martina Söderman; Samuel Rhedin; Thomas Tolfvenstam; Maria Rotzén-Östlund; Jan Albert; Kristina Broliden; Anna Lindblom
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

Review 2.  Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety.

Authors:  Giuseppe La Torre; Alice Mannocci; Vittoria Colamesta; Valeria D'Egidio; Cristina Sestili; Antonietta Spadea
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-09-01       Impact factor: 2.576

3.  Assessment of respiratory tract viruses in febrile neutropenic etiology in children and comparison with healthy children with upper/lower respiratory tract infection.

Authors:  Ayse Bozkurt Turhan; Tercan Us; Ener Cagri Dinleyici; Gonca Kilic Yildirim; Nilgun Kasifoglu; Zeynep Canan Ozdemir; Ozcan Bor
Journal:  North Clin Istanb       Date:  2021-01-05

4.  A Quality Improvement Initiative to Increase and Sustain Influenza Vaccination Rates in Pediatric Oncology and Stem Cell Transplant Patients.

Authors:  Chris I Wong; Amy L Billett; Shicheng Weng; Kelly Eng; Usha Thakrar; Kimberly J Davies
Journal:  Pediatr Qual Saf       Date:  2018-01-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.